Statera Starts Dosing In Acute COVID-19 Trial

Statera Biopharma Inc STAB has enrolled and randomized the first patient, with several more in screening for an initial study to evaluate STAT-205 as a potential oral treatment for COVID-19. 

  • STAT-205 is an immune-modulator designed to decrease elevated inflammatory responses associated with cytokine production and modulate the Th1/Th2 helper cells to control immune dysfunction.
  • The Company expects preliminary trial results in 2022.
  • The randomized, single-blind, placebo-controlled study will enroll 24 patients aged 18 years or older who test positive for acute SARS-CoV-2 and show symptoms of mild infection that are at high risk for disease progression. 
  • The study is designed to assess the pharmacokinetics (PK), early predictive biomarkers, and safety of STAT-205.
  • In preclinical in vitro studies, STAT-205 demonstrated the potential to inhibit the replication of coronaviruses in human lung cells.
  • Price Action: STAB shares closed 4.09% lower at $2.20 during after-hours trading on Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!